Cryosite Limited

CTE.ASX

Health Care

The Company provides an integrated clinical trial logistics service, biological storage and sample management service, including: the storage of cord blood stem cells for private use.

Market Data

Price

$1.100

+0.0%
Market Cap

$52.2M

P/E Ratio

24.9x

EPS

$0.043

Div. Yield

1.87%

52-Week Change

+0.1%

Latest Earnings

Appendix 4D and Half Year Accounts

26 February 2026

Revenue
$8.27
+25.0% YoY
NPAT
$1.14
+36.0% YoY
EPS
$0.02
Dividend
$0.00

Cryosite delivered strong HY26 results with revenue up 25% to $8.3M and NPAT up 36% to $1.1M, driven by broad-based growth across clinical trials, biologics and advanced therapies. The company doubled its storage capacity by acquiring a new warehouse facility in Auburn NSW for $10.1M, funded through cash and a $6.65M NAB loan facility. Key points: Strong broad-based growth across all temperature-controlled segments with operational volumes up 30% year-on-year; Ultra-Frozen and Cryogenic segment revenue increased 63% to $1.2M with EBITDA up 44%; Successfully doubled storage capacity through acquisition of Auburn warehouse facility

Recent Announcements

27 May 2026 Guidance Positive

Trading Update - Financial Year-to-Date - 30 April 2026

Cryosite Limited (ASX: CTE) reported strong financial performance for the ten months to 30 April 2026, with revenue up 22% to $13.8m and EBITDA up 28% to $3.4m, driven by growing clinical trial activity and ultra-frozen/cryogenic storage demand. The company completed capacity expansion at its Ferndell Street facility, refinanced its NAB debt facility to 2030, and is commissioning its newly acquired Adderley Street warehouse on schedule.

26 Feb 2026 Actual Results Positive

Appendix 4D and Half Year Accounts

Cryosite delivered strong HY26 results with revenue up 25% to $8.3M and NPAT up 36% to $1.1M, driven by broad-based growth across clinical trials, biologics and advanced therapies. The company doubled its storage capacity by acquiring a new warehouse facility in Auburn NSW for $10.1M, funded through cash and a $6.65M NAB loan facility. Key points: Strong broad-based growth across all temperature-controlled segments with operational volumes up 30% year-on-year; Ultra-Frozen and Cryogenic segment revenue increased 63% to $1.2M with EBITDA up 44%; Successfully doubled storage capacity through acquisition of Auburn warehouse facility

Get real-time alerts for CTE

Receive AI-powered earnings summaries and instant notifications when Cryosite Limited releases results.

Register Free